JusticeItaly Official institution

Italy withdraws marketing permission for Ondansetron Accord medicine

Italy's medicines regulator, AIFA, announced on 7 November 2026 that it is withdrawing the marketing permission for the human medicine Ondansetron Accord. The withdrawal follows a request from the company that holds the permission to give it up. The notice reference is 26A05795; the document excerpt provided does not give further details.

This summary was generated by AI; the official source prevails.

What does it mean?

Ondansetron Accord is a medicine that can no longer be legally sold in Italy under its current permission. The company asked to give up that permission, so the regulator has formally cancelled it.

Who is affected?

Patients who use Ondansetron Accord in Italy and the pharmacies and companies that supply it.

What changes?

Until now the medicine Ondansetron Accord was authorized for sale in Italy; now that permission is being withdrawn.